MENTOR
Membranous Nephropathy Trial of Rituximab
Patient / Population Intervention / Exposure Comparison Outcome
In 130 patients with membranous nephropathy at moderate-to-high risk, rituximab achieved more complete or partial remission at 24 months than cyclosporine.
N
130
Design
Open-label RCT
Endpoint
Complete or partial remission of proteinuria at month 24
Relevance
2
ResultRituximab 60% vs cyclosporine 20% at 24mo (risk difference 40pp, 95% CI 25-55, P<0.001 superiority); noninferior at 12mo (60% vs 52%, P=0.004).
Fervenza FC, et al. N Engl J Med. 2019;381(1):36-46. 10.1056/NEJMoa1814427
Discussion & critique
Established rituximab as a first-line option in KDIGO 2021; deeper and earlier anti-PLA2R decline than with cyclosporine.